B. Klein

B. Klein, C. Rebouissou, N. Mechti, 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Letter to the editor: The bone‐resorbing activity of interleukin‐6

B. Klein, R. Bataille, 1991 .

Interleukin 2 production in B cell chronic lymphocytic leukemia.

M. Jourdan, B. Klein, T. Commes, 1985, Blood.

CD5 B lymphocyte antigen in monoclonal gammopathy

B. Klein, R. Bataille, X. Zhang, 1992, American journal of hematology.

The CD24 antigen discriminates between pre-B and B cells in human bone marrow.

B. Klein, R. Bataille, T. Lavabre‐Bertrand, 1990, Journal of immunology.

Myeloma of T Cells from Patients with Multiple Activity and Decreases CD45RA Expression Lenalidomide Enhances Antigen-Specific

B. Klein, D. Hose, H. Goldschmidt, 2011 .

Hairy cell transformation of a B-cell chronic lymphocytic leukemia: a morphological, cytochemical, phenotypic and molecular study.

B. Klein, G. Delsol, G. Laurent, 1991, Leukemia.

Gene expression-based risk score in diffuse large B-cell lymphoma

B. Klein, J. Moreaux, C. Bret, 2012, Oncotarget.

Embryonic stem cells or induced pluripotent stem cells? A DNA integrity perspective.

B. Klein, J. de Vos, J. Lemaître, 2013, Current gene therapy.

Human peripheral blood B‐cell compartments: A crossroad in B‐cell traffic

A Orfao, R F Vogt, G E Marti, 2010, Cytometry. Part B, Clinical cytometry.

Interleukin-6 in human multiple myeloma.

B. Klein, R. Bataille, X. Zhang, 1995, Blood.

The human cumulus--oocyte complex gene-expression profile.

Bernard Klein, Véronique Pantesco, Said Assou, 2006, Human reproduction.

A gene expression signature shared by human mature oocytes and embryonic stem cells

Bernard Klein, Outi Hovatta, Véronique Pantesco, 2009, BMC Genomics.

STUDY OF CELL DEATH IN FRIEND LEUKAEMIA

L. Feinendegen, B. Klein, C. Jasmin, 1976, Cell and tissue kinetics.

gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro

B. Klein, R. Bataille, E. Caron, 1993 .

C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.

B. Klein, R. Bataille, M. Boccadoro, 1992, Blood.

Myeloproliferative virus, a cloned murine sarcoma virus with spleen focus-forming properties in adult mice

B. Klein, W. Ostertag, H. Eisen, 1980, Journal of virology.

GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells

Thierry Fest, Thierry Rème, Dirk Hose, 2015, PLoS Comput. Biol..

Etiology of Paget's disease of bone: A new perspective

B. Klein, R. Bataille, 1992, Calcified Tissue International.

Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients

B. Klein, J. Moreaux, T. Commes, 2014, BioMed research international.

of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.

B. Klein, E. Samra, 2014 .

Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells

T. Rème, J. Rossi, B. Klein, 2009, British journal of haematology.

Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays.

J. D. Vos, K. Tarte, G. Requirand, 2001, Blood.

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2017, Leukemia.

Immunosuppression in Multiple Myeloma Kaposi's Sarcoma-Associated Herpesvirus Is Not Detected With

K. Tarte, M. Jourdan, J. Rossi, 2013 .

Evidence against KSHV infection in the pathogenesis of multiple myeloma.

K. Tarte, B. Klein, S. Olsen, 1998, Virus research.

Kaposi's sarcoma-associated herpesvirus is not detected with immunosuppression in multiple myeloma.

K. Tarte, M. Jourdan, B. Klein, 1998, Blood.

Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells.

R. X. Sun, B. Klein, G. Ciliberto, 1996, Blood.

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma

T. Rème, J. Rossi, B. Klein, 2012, PloS one.

Concanavalin A-induced interferon gamma production by murine spleen cells and T cell lines. Lack of correlation with Lyt 1,2 phenotype.

B. Klein, P. Altevogt, F. Marcucci, 1984, Immunobiology.

Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation.

K. Tarte, B. Klein, F. Zhan, 2003, Blood.

Embryonic stem cell markers expression in cancers.

B. Klein, J. Moreaux, D. Hose, 2009, Biochemical and biophysical research communications.

Interleukin-6 as a Therapeutic Target

Bernard Klein, Michel Jourdan, M. Jourdan, 2015, Clinical Cancer Research.

Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma1

Hartmut Goldschmidt, Dirk Hose, Bernard Klein, 2009, The Journal of Immunology.

MMSET is overexpressed in cancers: link with tumor aggressiveness.

B. Klein, J. Moreaux, A. Kassambara, 2009, Biochemical and biophysical research communications.

Cancer-Testis Antigens in Multiple Myeloma PCR Analyses Identify Novel Potential Gene Expression Profiling and Real-Time

G. Requirand, T. Rème, B. Klein, 2009 .

APRIL is overexpressed in cancer: link with tumor progression

B. Klein, J. Moreaux, J. de Vos, 2009, BMC Cancer.

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

V. Pantesco, T. Rème, B. Klein, 2012, Haematologica.

Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication.

B. Klein, W. Vainchenker, N. Debili, 1991, Blood.

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

M. Jourdan, B. Klein, R. Bataille, 1989, Blood.

Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin‐6 signal transducer gp130 1

B. Klein, K. Bendtzen, M. Svenson, 1997, FEBS letters.

Identification of a novel antigenic structure of the human receptor for interleukin‐6 involved in the interaction with the glycoprotein 130 chain

B. Klein, J. Liautard, J. Brochier, 1996, Immunology.

Interleukin‐6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti‐gp130 monoclonal antibodies

B. Klein, P. Heinrich, G. Müller-Newen, 1995, European journal of immunology.

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients

B. Klein, J. Moreaux, T. Commes, 2012, Oncotarget.

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma

T. Rème, B. Klein, P. Laharrague, 2007, Leukemia.

Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma

B. Klein, M. Boccadoro, S. Iida, 1997, Nature Genetics.

Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.

M. Jourdan, B. Klein, R. Bataille, 1994, Blood.

ETV6 mutations and loss in AML-M0

B. Klein, M. Giphart-Gassler, B. Morolli, 2008, Leukemia.

ETV 6 mutations and loss in AML-M 0

B. Klein, H. Vrieling, L. Impera, 2008 .

Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins

M. Jourdan, B. Klein, J. Moreaux, 2012, Leukemia.

Microarray‐based understanding of normal and malignant plasma cells

K. Tarte, T. Rème, M. Jourdan, 2006, Immunological reviews.

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

B. Klein, J. Moreaux, G. Cartron, 2019, Cancers.

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2014, Oncotarget.

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.

M. Jourdan, B. Klein, J. Sany, 1991, Blood.

Interleukin-l0 Is a Proliferation Factor But Not a Differentiation Factor for Human Myeloma Cells

B. Klein, R. Bataille, J. Harousseau, 2002 .

Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma.

B. Klein, J. Cigudosa, S. Jhanwar, 1998, Blood.

Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation

K. Tarte, T. Rème, M. Jourdan, 2011, The Journal of Immunology.

An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization.

M. Jourdan, B. Klein, D. Hose, 2009, Blood.

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

V. Pantesco, T. Rème, J. Rossi, 2005, Blood.

BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone

K. Tarte, T. Rème, J. Rossi, 2003 .

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma

J. D. Vos, G. Requirand, T. Rème, 2006, Oncogene.

Gene expression of anti‐ and pro‐apoptotic proteins in malignant and normal plasma cells

V. Pantesco, T. Rème, M. Jourdan, 2009, British journal of haematology.

Effects of myeloproliferative sarcoma virus on the pluripotential stem cell and granulocyte precursor cell populations of DBA/2 mice.

B. Klein, W. Ostertag, C. Jasmin, 1981, Journal of the National Cancer Institute.

Myeloproliferative sarcoma virus: Its effects on erythropoiesis in adult DBA/2J mice

B. Klein, W. Ostertag, B. Fagg, 1983, Journal of cellular physiology.

Study of a virus-induced myeloproliferative syndrome associated with tumor formation in mice.

B. Klein, B. Caillou, M. Le Bousse-Kerdilès, 1980, European journal of cancer.

Analysis of the myeloproliferative sarcoma virus genome: limited changes in the prototype lead to altered target cell specificity

B. Klein, W. Ostertag, C. Jasmin, 1981, Journal of virology.

Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

B. Klein, R. Bataille, X. Zhang, 1989, Blood.

Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells

J. D. Vos, M. Jourdan, J. Rossi, 2002, Oncogene.

Constitutive production of interleukin-6 and immunologic features in cardiac myxomas.

M. Jourdan, B. Klein, R. Bataille, 1990, Arthritis and rheumatism.

Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies.

M. Jourdan, B. Klein, J. Liautard, 1994, European cytokine network.

Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.

B. Klein, R. Bataille, J. Wijdenes, 1993, Cytokine.

A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1

B. Klein, P. Laurent, J. Post, 1996, British journal of haematology.

No detectable malignant B cells in the peripheral blood of patients with multiple myeloma

B. Klein, R. Bataille, T. Commes, 1989, British journal of haematology.

EZH2 in normal hematopoiesis and hematological malignancies

B. Klein, J. Moreaux, Giacomo Cavalli, 2015, Oncotarget.

JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells

K. Tarte, M. Jourdan, B. Klein, 2000, British journal of haematology.

DNA repair pathways in human multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2013, Cell cycle.

Cytokines in Multiple Myeloma

J. D. Vos, B. Klein, 2004 .

Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors

J. D. Vos, M. Jourdan, B. Klein, 2000, Leukemia.

A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma.

K. Tarte, J. Rossi, B. Klein, 1998, Blood.

Dendritic cell-based vaccine: a promising approach for cancer immunotherapy

K. Tarte, B. Klein, Bernard Klein, 1999, Leukemia.

Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy

B. Klein, M. Mohty, J. Eliaou, 2001, Bone Marrow Transplantation.

Human autologous rosettes. IV. Their relation with interleukin 2 activity production and natural killer cells in cancer patients.

B. Klein, B Klein, D Zagury, 1984, Cellular immunology.

Induction of Human T Colony Formation by Phorbol Myristate Acetate

M. Jourdan, B. Klein, B. Serrou, 1983, Scandinavian journal of immunology.

Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients

B. Klein, J. Daurès, D. Pouessel, 2006, Bone Marrow Transplantation.

Myeloproliferative syndrome induced by MPSV in DBA/2 mice: presence of a mixed-colonies promoting activity (MPA) in the spleen.

B. Klein, M. Le Bousse-Kerdilès, W. Ostertag, 1983, Blood.

A study of added GM-CSF independent granulocyte and macrophage precursors in mouse spleen infected with myeloproliferative sarcoma virus (MPSV).

B. Klein, W. Ostertag, C. Jasmin, 1982, Experimental hematology.

MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma.

R. X. Sun, B. Klein, M. Fabbro, 1998, Clinical and laboratory haematology.

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value

B. Klein, J. Moreaux, P. Pasero, 2016, Biomarker Research.

DNA methylation score is predictive of myeloma cell sensitivity to 5‐azacitidine

B. Klein, J. Moreaux, D. Hose, 2014, British journal of haematology.

DNA repair in diffuse large B‐cell lymphoma: a molecular portrait

B. Klein, J. Moreaux, A. Constantinou, 2015, British journal of haematology.

Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma

B. Klein, J. Moreaux, C. Bret, 2013, Cell cycle.

Immunomodulating IL-6 activity by murine monoclonal antibodies.

B. Klein, R. Bataille, E. Legouffe, 1995, International journal of immunopharmacology.

APRIL and TACI interact with syndecan‐1 on the surface of multiple myeloma cells to form an essential survival loop

M. Jourdan, J. Rossi, B. Klein, 2009, European journal of haematology.

TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.

T. Rème, M. Jourdan, B. Klein, 2007, Haematologica.

Kaposi's sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality.

K. Tarte, B. Klein, Y. Chang, 1999, Blood.

Thymosin β4 in multiple myeloma: friend or foe

B. Klein, D. Hose, K. Vanderkerken, 2010, Annals of the New York Academy of Sciences.

Interleukin‐6 dependence of advanced malignant plasma cell dyscrasias

B. Klein, R. Bataille, Xue Zhang, 1992, Cancer.

Low dose of deoxyguanosine increases IL-2 receptors of IL-2-dependent cultured T cells.

B. Klein, J. Yata, T. Noma, 1984, Immunology.

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

G. Requirand, T. Rème, B. Klein, 2013, British Journal of Cancer.

Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma

B. Klein, D. Hose, H. Goldschmidt, 2011, The Journal of Immunology.

Modeling risk stratification in human cancer

Thierry Rème, Dirk Hose, Charles Theillet, 2013, Bioinform..

Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis1

P. Raynaud, V. Pantesco, T. Rème, 2007, The Journal of Immunology.

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells

T. Rème, B. Klein, J. Moreaux, 2013, PloS one.

Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation

M. Jourdan, B. Klein, D. Hose, 2010, Leukemia.

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Bart Barlogie, Hartmut Goldschmidt, Dirk Hose, 2009, Blood.

IFN-α Is a Survival Factor for Human Myeloma Cells and Reduces Dexamethasone-Induced Apoptosis

M. Jourdan, J. Rossi, B. Klein, 1998, The Journal of Immunology.

Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

K. Tarte, M. Jourdan, B. Klein, 1999, European cytokine network.

A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments

Hartmut Goldschmidt, Thierry Rème, Dirk Hose, 2008, BMC Bioinformatics.

Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells

Bernard Klein, Alberto Orfao, Martin Perez-Andres, 2010, Haematologica.

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays

T. Rème, M. Jourdan, J. Rossi, 2010, BMC Cancer.

Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.

B. Klein, R. Bataille, J. Wijdenes, 1995, Blood.

Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells.

K. Tarte, J. Rossi, B. Klein, 1999, Journal of immunology.

Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.

K. Tarte, T. Rème, J. Rossi, 2002, Blood.

Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B‐cell malignancies

B. Klein, J. Grosgeorge, C. Bastard, 1993, Genes, chromosomes & cancer.

Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas.

B. Klein, R. Bataille, J. Revillard, 1988, Journal of steroid biochemistry.

A highly sensitive quantitative bioassay for human interleukin-11.

B. Klein, R. Bataille, M. Amiot, 1994, Journal of immunological methods.

High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo

B. Klein, R. Bataille, J. Wijdenes, 1992, European journal of immunology.

Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells.

B. Klein, D. Zagury, B. Serrou, 1983, Immunology letters.

B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

K. Tarte, J. Rossi, B. Klein, 2007, Experimental hematology.

Control of human T-colony formation by interleukin-2.

M. Jourdan, B. Klein, T. Commes, 1985, Immunology.

Identification of HLA‐A2 restricted T‐cell epitopes within the conserved region of the immunoglobulin G heavy‐chain in patients with multiple myeloma

B. Klein, D. Hose, H. Goldschmidt, 2008, European journal of haematology.

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

B. Klein, D. Hose, H. Goldschmidt, 2006, Experimental hematology.

Phenotypic analysis of human myeloma cell lines.

M. Jourdan, B. Klein, G. Lenoir, 1989, Blood.

molecule-6 cells through carcinoembryonic antigen-related cell adhesion Tumor cells in multiple myeloma patients inhibit myeloma-reactive

T. Rème, J. Rossi, B. Klein, 2013 .

Controlled Epstein–Barr virus reactivation after allogeneic transplantation is associated with improved survival

J. Rossi, B. Klein, N. Fegueux, 2014, European journal of haematology.

Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24

B. Klein, D. Hose, H. Goldschmidt, 2009, Journal of immunotherapy.

Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop.

B. Klein, R. Bataille, V. Costes, 1996, Blood.

Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.

T. Rème, B. Klein, D. Hose, 2011, Experimental hematology.

Rituximab Activity Is Potentiated by GM-CSF in Patients with Relapsed, Follicular Lymphoma: Results of a Phase II Study.

J. Rossi, B. Klein, P. Quittet, 2005 .

Induction in rats of paranasal sinus carcinomas with radioactive cerium chloride.

B. Klein, C. Jasmin, F. Smadja-joffe, 1977, Journal of the National Cancer Institute.

Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.

B. Klein, D. Hose, A. Seckinger, 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2016, British Journal of Cancer.

Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications

T. Rème, M. Jourdan, J. Rossi, 2007, Clinical Cancer Research.

Input of DNAMicroarrays to Identify Novel Mechanisms in Multiple Myeloma Biology andTherapeutic Applications

T. Rème, B. Klein, H. Goldschmidt, 2007 .

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Axel Benner, Thomas Hielscher, Bart Barlogie, 2008, Blood.

Spontaneous secretion of tumor necrosis factor‐beta by human myeloma cell lines

M. Jourdan, B. Klein, R. Bataille, 1989, Cancer.

The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

T. Rème, B. Klein, J. Moreaux, 2011, Srpski arhiv za celokupno lekarstvo.

Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production

J. Rossi, B. Klein, R. Bataille, 1998, British journal of haematology.

MYEOV is a prognostic factor in multiple myeloma.

T. Rème, B. Klein, J. Moreaux, 2010, Experimental hematology.

Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis?

B. Klein, R. Bataille, M. Boccadoro, 1993, Blood.

Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.

B. Klein, B. Ness, M. Oken, 1998, Blood.

The bone-resorbing activity of interleukin-6.

B. Klein, R. Bataille, R. Bataille, 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Characterization of human FCRL4-positive B cells

K. Tarte, M. Jourdan, B. Klein, 2017, PloS one.

Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.

B. Klein, J. Moreaux, R. Bataille, 2012, Blood cells, molecules & diseases.

An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.

M. Jourdan, J. Rossi, B. Klein, 2004, Blood.

Interrelationship between autoimmunity and B-lymphoid cell oncogenesis in humans.

B. Klein, R. Bataille, J. Sany, 1989, Clinical and experimental rheumatology.

Studies on erythroid-committed precursor cells in the polycythaemic mouse.

B. Klein, R. Schofield, S. Kyffin, 1977, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance [letter; comment]

B. Klein, R. Bataille, 1992 .

An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line.

B. Klein, Y. Wang, Y. Qiu, 1999, Hybridoma.

Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage

V. Pantesco, M. Jourdan, B. Klein, 2016, Cell cycle.

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors

G. Requirand, T. Rème, B. Klein, 2012, Molecular Cancer Therapeutics.

MCT-12-0721 2685..2692

G. Requirand, T. Rème, B. Klein, 2012 .

Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features

B. Klein, J. Moreaux, C. Bony, 2020, Stem Cell Research & Therapy.

Tumoral Sample Peripheral blood Pleural effusion Peripheral blood Pleural effusion Peripheral blood Peripheral blood Peripheral blood Peripheral blood Peripheral blood Bone marrow and the percentages of myeloma cells

M. Jourdan, B. Klein, R. Bataille, 2002 .

IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors

K. Tarte, M. Jourdan, B. Klein, 2014, Leukemia.

The Bcl‐2 family member Bfl‐1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti‐apoptotic factor for myeloma cells

K. Tarte, M. Jourdan, B. Klein, 2004, British journal of haematology.

Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2013, Haematologica.

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

B. Klein, M. Bozonnat, J. Widjenes, 2005, Bone Marrow Transplantation.

Cytokine-binding proteins: stimulating antagonists.

B. Klein, H. Brailly, 1995, Immunology today.

Tocilizumab in Treatment for Patients With COVID-19.

J. Rossi, B. Klein, Hao-Chun Chiang, 2021, JAMA Internal Medicine.

CLONAL REARRANGEMENT OF IMMUNOGLOBULIN GENES IN THE PERIPHERAL BLOOD OF MULTIPLE MYELOMA PATIENTS

B. Klein, R. Bataille, A. Lichtenstein, 1989, British journal of haematology.

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma

B. Klein, D. Hose, H. Goldschmidt, 2010, Haematologica.

Serum beta-2-microglobulin (beta 2m) in myeloma: toward a simple prognostic stratification using beta 2M and acute-phase proteins? [letter; comment]

B. Klein, R. Bataille, 1991 .

Amazonia!: An Online Resource to Google and Visualize Public Human whole Genome Expression Data

Thierry Rème, Tanguy Le Carrour, John De Vos, 2010 .

powerful myeloma staging system C-reactive protein and beta-2 microglobulin produce a simple and

B. Klein, R. Bataille, M. Boccadoro, 2013 .

BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone

K. Tarte, T. Rème, J. Rossi, 2003 .

Large scale and clinical grade purification of syndecan-1+ malignant plasma cells.

R. X. Sun, B. Klein, J. Wijdenes, 1997, Journal of immunological methods.

Functional interaction of the gp80 and gp130 IL-6 receptors in human B cell malignancies.

B. Klein, J. Liautard, J. Brochier, 1998, Clinical and laboratory haematology.

A ciliary neurotrophic factor-sensitive human myeloma cell line.

B. Klein, M. Hallet, X. Zhang, 1996, Experimental hematology.

A Phase I/II Study of TACI-Ig To Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Multiple Myeloma or Active Previously-Treated Waldenström’s Macroglobulinemia.

G. Requirand, J. Rossi, B. Klein, 2005 .

A Phase I/II Study of Atacicept (TACI-Ig) To Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Multiple Myeloma (MM) or Active Previously Treated Waldenstrom’s Macroglobulinemia (WM).

J. Rossi, B. Klein, J. Moreaux, 2006 .

Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model

T. Rème, B. Klein, J. Brochier, 2001, British journal of haematology.

NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm

B. Klein, J. Moreaux, D. Hose, 2010, Genes, chromosomes & cancer.

Gene Expression Profiling and Real-Time PCR Analyses Make It Possible To Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma.

J. D. Vos, G. Requirand, T. Rème, 2007 .

Inhibiting IL-6 in human multiple myeloma.

B. Klein, R. Bataille, J. Harousseau, 1992, Current topics in microbiology and immunology.

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells

B. Klein, J. Moreaux, D. Hose, 2015, Haematologica.

Conserved natural humoral immunity to thyroglobulin in patients with multiple myeloma

B. Klein, R. Bataille, B. Pau, 1992, British journal of haematology.

Cellular proliferation kinetics of the murine sarcoma induced by the Moloney sarcoma virus

B. Klein, C. Jasmin, F. Smadja-joffe, 1982, Cell and tissue kinetics.

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value

B. Klein, J. Moreaux, P. Pasero, 2016, Biomarker Research.

Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features

B. Klein, J. Moreaux, C. Bony, 2020, Stem Cell Research & Therapy.

Total fertilization failure and molecular abnormalities in metaphase II oocytes.

T. Rème, B. Klein, J. de Vos, 2008, Reproductive biomedicine online.

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

K. Tarte, T. Rème, J. Rossi, 2004, Blood.

Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130

B. Klein, R. Bataille, G. Yancopoulos, 1994, The Journal of experimental medicine.

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and

K. Tarte, B. Klein, E. Jourdan, 2007 .

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

K. Tarte, T. Rème, J. Rossi, 2003 .

Myeloproliferative sarcoma virus (MPSV), a new tool for the study of hematopoiesis.

B. Klein, M. Le Bousse-Kerdilès, W. Ostertag, 1981, Blood cells.

Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor.

R. X. Sun, B. Klein, N. Cotte, 1997, Cytokine.

DNA repair pathways in human multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2013, Cell cycle.

Gene expression-based risk score in diffuse large B-cell lymphoma

B. Klein, J. Moreaux, C. Bret, 2012, Oncotarget.

Interleukin-6 in human multiple myeloma.

B. Klein, R. Bataille, Z. Lu, 1995, Blood.

No expansion of the pre-B and B-cell compartments in the bone marrow of patients with multiple myeloma.

B. Klein, R. Bataille, X. Zhang, 1991, Cancer research.

Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease

B. Klein, D. Hose, A. Seckinger, 2012 .

Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb.

B. Klein, J. de Vos, P. Autissier, 1998, International immunology.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

T. Rème, J. Rossi, B. Klein, 2011, Haematologica.

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

T. Rème, J. Rossi, B. Klein, 2012 .

Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation.

K. Tarte, B. Klein, F. Zhan, 2003, Blood.

Determined by Microarray Analysis Expression Patterns and Prognosis Value Cancer/Testis Genes in Multiple Myeloma:

J. D. Vos, P. Raynaud, V. Pantesco, 2007 .

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

B. Klein, D. Hose, H. Goldschmidt, 2006, Experimental hematology.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

T. Rème, M. Jourdan, B. Klein, 2011, Haematologica.

BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone

K. Tarte, J. Rossi, B. Klein, 2003 .

Characterization of Mesenchymal Stem Cells Abnormalities in Multiple Myeloma.

T. Rème, B. Klein, P. Laharrague, 2006 .

Thymosin β4 in multiple myeloma: friend or foe

B. Klein, D. Hose, K. Vanderkerken, 2010, Annals of the New York Academy of Sciences.

Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

B. Klein, P. Moreau, H. Avet-Loiseau, 2012, Cancer research.

The relationship between autoimmune states and B cell proliferations.

B. Klein, R. Bataille, B. Durie, 1989, The Journal of rheumatology.

Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells

B. Klein, H. Johnsen, M. Pérez‐Andrés, 2010, Haematologica.

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

V. Pantesco, T. Rème, B. Klein, 2012, Haematologica.

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

G. Requirand, J. Rossi, B. Klein, 2012, Oncotarget.

Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance.

B. Klein, R. Bataille, 1992, Blood.

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

G. Requirand, T. Rème, B. Klein, 2011, Blood.

This information is current as Granulocyte Colony-Stimulating Factor High-Dose Cyclophosphamide and in Stem Cell Autografts by Mobilization with Functional Regulatory T Cells Are Collected

K. Tarte, G. Requirand, J. Rossi, 2017 .